Capital World Investors Purchases 286,493 Shares of Pfizer Inc. $PFE

Capital World Investors lifted its position in shares of Pfizer Inc. (NYSE:PFE) by 2.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 14,146,696 shares of the biopharmaceutical company’s stock after purchasing an additional 286,493 shares during the period. Capital World Investors owned about 0.25% of Pfizer worth $360,457,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in PFE. Peak Asset Management LLC increased its position in Pfizer by 1.4% in the 2nd quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock valued at $697,000 after acquiring an additional 402 shares during the period. Community Bank & Trust Waco Texas raised its stake in shares of Pfizer by 0.6% during the third quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company’s stock valued at $1,703,000 after acquiring an additional 412 shares during the last quarter. CVA Family Office LLC lifted its holdings in shares of Pfizer by 3.3% during the third quarter. CVA Family Office LLC now owns 12,915 shares of the biopharmaceutical company’s stock worth $329,000 after purchasing an additional 413 shares during the period. Boltwood Capital Management grew its stake in shares of Pfizer by 0.7% in the third quarter. Boltwood Capital Management now owns 58,274 shares of the biopharmaceutical company’s stock worth $1,485,000 after purchasing an additional 420 shares during the last quarter. Finally, Beverly Hills Private Wealth LLC grew its stake in shares of Pfizer by 1.5% in the third quarter. Beverly Hills Private Wealth LLC now owns 27,955 shares of the biopharmaceutical company’s stock worth $712,000 after purchasing an additional 421 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 0.5%

Shares of Pfizer stock opened at $27.30 on Thursday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.94. The stock has a 50 day moving average price of $26.43 and a two-hundred day moving average price of $25.50. The stock has a market capitalization of $155.24 billion, a PE ratio of 20.07 and a beta of 0.47.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company had revenue of $17.56 billion for the quarter, compared to analyst estimates of $16.93 billion. During the same period in the prior year, the firm earned $0.63 earnings per share. Pfizer’s revenue for the quarter was down 1.2% on a year-over-year basis. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 6th. Shareholders of record on Friday, January 23rd were paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.3%. The ex-dividend date of this dividend was Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is 126.47%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approved Pfizer’s GLP‑1 weight‑management drug Xianweiying for long‑term use in overweight/obese adults — opens a large new commercial market and intensifies competition in the GLP‑1 class, supporting upside to revenue growth if launch execution is strong. Pfizer’s Weight Management Drug Wins China Approval
• Positive Sentiment: Pfizer completed a Phase 2 toddler study for its next‑generation pneumococcal vaccine — a positive clinical read that advances a pipeline asset with potential to drive future vaccine revenues and support longer‑term growth. Pfizer Advances Next-Gen Pneumococcal Vaccine With Completed Phase 2 Toddler Study
• Neutral Sentiment: Pfizer commentary on regulatory agility — company regulatory lead outlines strategies to navigate shifting approval environments; useful for long‑term program risk management but unlikely to move the stock near‑term. Be nimble, be ready: how to tackle regulatory uncertainty in clinical trials
• Neutral Sentiment: Valuation pieces (Yahoo/Seeking Alpha) debate whether Pfizer’s current price captures post‑pandemic pipeline and patent risks — these analyses reinforce mixed investor views: stable cash flows and dividends vs. legacy product cliffs and pipeline uncertainty. Does Pfizer (PFE) Offer Value After Post Pandemic Pipeline And Patent Concerns
• Negative Sentiment: Patent/legal developments in the sector affected peers and related stocks — a patent “shake‑up” around tafamidis helped BridgeBio trade higher, illustrating ongoing IP risk and competitive uncertainties that can indirectly pressure Pfizer where patent battles exist. Why BridgeBio Leapfrogged Its 50-Day Line On Pfizer’s Patent Shake-Up
• Negative Sentiment: Sector headlines (e.g., BioNTech leadership changes) are creating rotation and volatility in vaccine/biotech names; while not directly about Pfizer, this can weigh on sentiment for large pharma stocks during risk‑off moves. BioNTech Cofounders To Step Down. Stock Crumbles.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on PFE shares. HSBC reaffirmed a “buy” rating and set a $29.00 target price on shares of Pfizer in a research report on Wednesday, December 10th. Argus raised Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target for the company in a research note on Monday, March 2nd. Wolfe Research set a $24.00 price objective on Pfizer and gave the stock an “underperform” rating in a research report on Wednesday, December 17th. Zacks Research upgraded Pfizer from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 24th. Finally, Scotiabank initiated coverage on shares of Pfizer in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, fourteen have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $28.05.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.